Literature DB >> 26887832

NLRP3 deletion protects against renal fibrosis and attenuates mitochondrial abnormality in mouse with 5/6 nephrectomy.

Wei Gong1, Song Mao1, Jing Yu1, Jiayu Song1, Zhanjun Jia1, Songming Huang1, Aihua Zhang2.   

Abstract

Progressive fibrosis in chronic kidney disease (CKD) is the well-recognized cause leading to the progressive loss of renal function. Emerging evidence indicated a pathogenic role of the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome in mediating kidney injury. However, the role of NLRP3 in the remnant kidney disease model is still undefined. The present study was undertaken to evaluate the function of NLRP3 in modulating renal fibrosis in a CKD model of 5/6 nephrectomy (5/6 Nx) and the potential involvement of mitochondrial dysfunction in the pathogenesis. Employing NLRP3(+/+) and NLRP3(-/-) mice with or without 5/6 Nx, we examined renal fibrotic response and mitochondrial function. Strikingly, tubulointerstitial fibrosis was remarkably attenuated in NLRP3(-/-) mice as evidenced by the blockade of extracellular matrix deposition. Meanwhile, renal tubular cells in NLRP3(-/-) mice maintained better mitochondrial morphology and higher mitochondrial DNA copy number, indicating an amelioration of mitochondrial abnormality. Moreover, NLRP3 deletion also blunted the severity of proteinuria and CKD-related hypertension. To further evaluate the direct role of NLRP3 in triggering fibrogenesis, mouse proximal tubular cells (PTCs) were subjected to transforming growth factor β1 (TGF-β1), and the cellular phenotypic changes were detected. As expected, TGF-β1-induced alterations of PTC phenotype were abolished by NLRP3 small interfering RNA, in line with a protection of mitochondrial function. Taken together, NLRP3 deletion protected against renal fibrosis in the 5/6 Nx disease model, possibly via inhibiting mitochondrial dysfunction.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  NLRP3 inflammasome; chronic kidney disease; mitochondrial dysfunction

Mesh:

Substances:

Year:  2016        PMID: 26887832     DOI: 10.1152/ajprenal.00534.2015

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  38 in total

Review 1.  The Emerging Role of Inflammasomes as Central Mediators in Inflammatory Bladder Pathology.

Authors:  Brian M Inouye; Francis M Hughes; Stephanie J Sexton; J Todd Purves
Journal:  Curr Urol       Date:  2017-12-30

2.  Chronic kidney disease-induced atrial structural remodeling and atrial fibrillation: more studies on the pathological mechanism are encouraged.

Authors:  Huiliang Qiu; Chunlan Ji; Huanlin Wu; Chuan Zou
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-05-10       Impact factor: 3.000

3.  Macrophage Uptake of Necrotic Cell DNA Activates the AIM2 Inflammasome to Regulate a Proinflammatory Phenotype in CKD.

Authors:  Takanori Komada; Hyunjae Chung; Arthur Lau; Jaye M Platnich; Paul L Beck; Hallgrimur Benediktsson; Henry J Duff; Craig N Jenne; Daniel A Muruve
Journal:  J Am Soc Nephrol       Date:  2018-02-09       Impact factor: 10.121

4.  Schwann cell transplantation exerts neuroprotective roles in rat model of spinal cord injury by combating inflammasome activation and improving motor recovery and remyelination.

Authors:  Mahboubeh Mousavi; Azim Hedayatpour; Keywan Mortezaee; Yousef Mohamadi; Farid Abolhassani; Gholamreza Hassanzadeh
Journal:  Metab Brain Dis       Date:  2019-06-04       Impact factor: 3.584

5.  [Dexmedetomidine preconditioning alleviates acute lung injury induced by intestinal ischemia-reperfusion in rats by inhibiting NLRP3 inflammasome activation].

Authors:  B Han; M Chen; C Yang; X Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-12-20

6.  The key role of NLRP3 and STING in APOL1-associated podocytopathy.

Authors:  Junnan Wu; Archana Raman; Nathan J Coffey; Xin Sheng; Joseph Wahba; Matthew J Seasock; Ziyuan Ma; Pazit Beckerman; Dorottya Laczkó; Matthew B Palmer; Jeffrey B Kopp; Jay J Kuo; Steven S Pullen; Carine M Boustany-Kari; Andreas Linkermann; Katalin Susztak
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

Review 7.  Immune mechanisms of hypertension.

Authors:  Grant R Drummond; Antony Vinh; Tomasz J Guzik; Christopher G Sobey
Journal:  Nat Rev Immunol       Date:  2019-08       Impact factor: 53.106

Review 8.  Inflammasome as an Effective Platform for Fibrosis Therapy.

Authors:  Ting-Ting Chen; Feng Xiao; Nan Li; Shan Shan; Meng Qi; Zi-Ying Wang; Sheng-Nan Zhang; Wei Wei; Wu-Yi Sun
Journal:  J Inflamm Res       Date:  2021-04-20

Review 9.  Mitochondrial DNA-Mediated Inflammation in Acute Kidney Injury and Chronic Kidney Disease.

Authors:  Lini Jin; Binfeng Yu; Ines Armando; Fei Han
Journal:  Oxid Med Cell Longev       Date:  2021-06-29       Impact factor: 6.543

10.  Angiotensin II Stimulates the NLRP3 Inflammasome to Induce Podocyte Injury and Mitochondrial Dysfunction.

Authors:  Min Zhao; Mi Bai; Guixia Ding; Yue Zhang; Songming Huang; Zhanjun Jia; Aihua Zhang
Journal:  Kidney Dis (Basel)       Date:  2018-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.